Viral Vectors and Plasmid DNA Manufacturing Market Size was valued
at USD 0.3 billion in 2022 and is projected to grow from USD 0.35 Billion in
2023 to USD 1.1 billion by 2032, exhibiting a compound annual growth rate
(CAGR) of 16.1% during the forecast period (2023 - 2032).
The Viral Vectors and Plasmid DNA Manufacturing Market witness robust growth, driven by
expanding applications in gene therapy, vaccine development, and
biopharmaceutical production. Demand surges as gene-based therapies gain
traction in treating genetic disorders, cancer, and infectious diseases.
Increasing R&D investments, technological advancements, and favorable
regulatory landscapes bolster market expansion. Viral vectors, including
lentivirus, adenovirus, and adeno-associated virus (AAV), alongside plasmid
DNA, serve as vital tools in genetic engineering. The market experiences
intensifying competition among key players focusing on scalability, safety, and
efficiency of production processes. Continuous innovation and strategic
collaborations propel the sector forward amid evolving healthcare demands.
The Viral Vectors and Plasmid DNA Manufacturing Market is
witnessing unprecedented growth, fueled by advancements in viral gene therapy
and vector purification techniques. As the demand for innovative gene therapies
surges, so does the need for efficient manufacturing processes to produce viral
vectors and plasmid DNA, crucial components in gene therapy treatments.
Viral gene therapy holds immense promise for treating a wide array
of genetic disorders and diseases by delivering therapeutic genes into target
cells using viral vectors. However, ensuring the safety and efficacy of these
therapies requires high-quality vectors and plasmid DNA. Vector purification
plays a pivotal role in this process, enabling the removal of impurities and
ensuring the vectors meet stringent quality standards.
Manufacturers in this market are investing heavily in research and
development to enhance vector purification methods, streamline manufacturing
processes, and scale up production to meet growing demand. Moreover,
advancements in biotechnology and genetic engineering are driving innovation,
leading to the development of more efficient viral vectors and plasmid DNA
constructs.
The Viral Vectors and Plasmid DNA Manufacturing Market is
characterized by intense competition and collaboration among key players to
expand their product portfolios, improve manufacturing capabilities, and meet
evolving regulatory requirements. As the field of gene therapy continues to
evolve, the market for viral vectors and plasmid DNA manufacturing is poised
for significant growth, offering new hope for patients suffering from genetic
disorders and chronic diseases.
Regional Analysis
Based on region, North America is expected to dominate the global
viral vector and plasmid DNA manufacturing market in 2020. Factors such as the
presence of a largenumber of centers and institutes engaged in the R&D of
advanced therapies and key players in this region involved in new product
launches, expansion, acquisition,and strategic collaborations are driving the
market growth. For instance, In March 2021, ABECMA (idecabtagenevicleucel), a
lentivirus-based gene therapy, received the US FDA approvalto treat R/R
multiple myeloma.
Europe is expected to hold the second-largest position in
the global viral vector and plasmid DNA manufacturing market in 2021. Key
factors attributing to the market growth are the increasing R&D spendings
to enhance research activities in the healthcare industry. For instance,
according to the data published in Eurostat in 2018, the EU spent approximately
348 USD million on Research & Development. The R&D expenditure as a
percentage of GDP was 2.18% in 2018, compared to 1.87 % in 2008.
Asia-Pacific is anticipated to be the fastest-growing
regional market over the assessment period due to the increasing prevalence of
target disorders and healthcare needs. Furthermore, the growth of the market in
the rest of the world is attributed to the rising penetration of advanced
healthcare technologies in research organizations focused on viral vector and
plasmid DNA manufacturing incountries such as Saudi Arabia and the UAE.
Developing countries such as Argentina, Brazil, and Colombia, among others in
Latin America, are also key contributors to the growth of the market.
Segmentation
The global viral vector and plasmid DNA manufacturing market has been segmented intovector type, workflow, disease type,
application, and end user.
By vector type, the market is segmented into plasmid DNA,
viral vector, non-viral vector. The viral vector segment represented the
dominant share in 2020, owing to the rising prevalence of target diseases and
disorders, the effectiveness of viral vectors in gene therapy delivery, and
rising research activities focused on viral vector-based gene & cell
therapies.
Based on the workflow, the market is segmented into upstream
processing, downstream processing. Downstream processing dominated the market
for viral vectors and plasmid DNA manufacturing in 2020. Increasing adoption of
downstream processing methods to help reduce contaminants originating from host
cells or culture media is driving the market growth of this segment.
On the basis of disease type, the market has been segmented into
genetic disorders, cancer, infectious diseases, and others. Cancer held the
largest market share in 2020 due to the increasing prevalence of cancer cases
globally. Furthermore, geneticdisordersare expected to be the fastest-growing
segment.
Based on application, the market is segmented into antisense &
RNAi therapy, gene therapy, cell therapy, vaccinology, and research. The
vaccinology segment dominated the market in 2020, owing tothe rising adoption
of viral vectors in vaccine development.
By end user, pharmaceutical & biopharmaceutical
companies and research institutes. Research institutes held a major share in
the global viral vectors and plasmid DNA manufacturing market. The increasing
number of research centers in gene and cell therapy coupled with rising
research activities for viral vectors and plasmid DNA is projected to increase
the demand for viral vectors in the global market.
Key Players
The global Viral Vector and Plasmid DNA
Manufacturing companies are Cognate BioServices, Inc. (US),
Catalent Pharma Solutions (US), Fujifilm Holdings Corporation (Japan), Johnson
& Johnson (US), Sanofi Corporation (France), F. Hoffmann-LA Roche Ltd
(Switzerland), 4D Molecular Therapeutics (US), Sirion Biotech GmbH (Germany),
Voyager Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Gene Therapy
Catapult (UK), UniQure (Netherlands), MassBiologics (US), Renova Therapeutics
(US) and Shenzhen SiBionoGeneTech Co., Ltd (China).
Related Reports:
Asia-Pacific Interventional
Cardiology
Blue Biotechnology
Membranous Nephropathy
Chordoma Disease
Operating Table Parts
For More
Information, Please Visit @ Market Research Future
Comments
Post a Comment